MedPath

A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

Phase 3
Completed
Conditions
Lung Diseases, Interstitial
Interventions
Registration Number
NCT03820726
Lead Sponsor
Boehringer Ingelheim
Brief Summary

The main objective is to assess long term tolerability and safety of treatment with oral nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) who have complete (and did not prematurely discontinue trial medication in) the phase III parent trial, INBUILD® (trial 1199.247).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
435
Inclusion Criteria
  • Male or female patients who completed the INBUILD® trial as planned and who did not prematurely discontinue blinded treatment.
  • Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial.
  • Women of childbearing potential (WOCBP)1 must continue to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly, as well as one barrier method, for 28 days prior to and 3 months after nintedanib administration. A list of contraception methods meeting these criteria is provided in the patient information
Exclusion Criteria
  • Any disease that may put the patient at risk when participating in this trial. Reconsider carefully all exclusion criteria of the INBUILD® trial. However, patients may qualify for participation even though exclusion criteria may have been met during the course of participation in INBUILD®, if the investigator's benefit-risk assessment remains favourable.
  • Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial
  • Patient not compliant in parent trial (INBUILD®), with trial medication or trial visits, according to investigator's judgement.
  • Previous enrolment in this trial. Further exclusion criteria apply.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
NintedanibNintedanibPatients taking 150 milligram (mg) bid blinded trial medication (active drug or placebo) at the end of INBUILD® started treatment with nintedanib 150 mg bid in this extension trial. Patients taking 100 mg bid blinded trial medication (active drug or placebo) at the end of INBUILD® started treatment with nintedanib in this extension trial either at 100 mg bid or at an increased dose of 150 mg bid at the discretion of the investigator orally as soft gelatine capsule, twice daily (bid), together with a glass of water (\~250 mL), in a dose interval of 12 hours. With an optional dose reduction to 100 mg bid temporarily or permanently to manage adverse events (AEs). The treatment had a duration of 96 weeks or until nintedanib was made available to the patients outside of the clinical trial. Treatment was stopped if any reason for withdrawal was met.
Primary Outcome Measures
NameTimeMethod
Number of Participants With Any Adverse EventsFrom first nintedanib intake until last nintedanib intake + 28 days of Residual effect period (REP), up to 1195 days.

Number of participants with adverse events over the course of the extension trial, AEs defined as any untoward medical occurrence in a patient administered with the investigational product and which does not necessarily have to have a causal relationship with this treatment.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (121)

National Hospital Organization Himeji Medical Center

🇯🇵

Hyogo, Himeji, Japan

HOP Civil

🇫🇷

Strasbourg, France

1stPavlov St.Med.Univ.St.-Petersburg Res.Inst.

🇷🇺

St. Petersburg, Russian Federation

Hospital Santa Creu i Sant Pau

🇪🇸

Barcelona, Spain

Royal Stoke University Hospital

🇬🇧

Stoke-on-Trent, United Kingdom

HOP Pasteur

🇫🇷

Nice, France

HOP Nord

🇫🇷

Marseille, France

Winnipeg Clinic

🇨🇦

Winnipeg, Manitoba, Canada

Icahn School of Medicine at Mount Sinai

🇺🇸

New York, New York, United States

University of California Los Angeles

🇺🇸

Los Angeles, California, United States

Duke University Medical Center

🇺🇸

Durham, North Carolina, United States

Emory University

🇺🇸

Atlanta, Georgia, United States

University of Texas Southwestern Medical Center

🇺🇸

Dallas, Texas, United States

University of Chicago

🇺🇸

Chicago, Illinois, United States

Johns Hopkins Hospital

🇺🇸

Baltimore, Maryland, United States

Beth Israel Deaconess Medical Center

🇺🇸

Boston, Massachusetts, United States

Brigham and Women's Hospital

🇺🇸

Boston, Massachusetts, United States

Diagnostics Research Group

🇺🇸

San Antonio, Texas, United States

Henry Ford Health System

🇺🇸

Detroit, Michigan, United States

Medical Arts and Research Center (MARC)

🇺🇸

San Antonio, Texas, United States

Toronto General Hospital

🇨🇦

Toronto, Ontario, Canada

A.O.U. Policlinico Vittorio Emanuele

🇮🇹

Catania, Italy

A.O.U. Senese Policlinico Santa Maria alle Scotte

🇮🇹

Siena, Italy

Poli Univ A. Gemelli

🇮🇹

Roma, Italy

University of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

National Jewish Health

🇺🇸

Denver, Colorado, United States

University of California Davis

🇺🇸

Sacramento, California, United States

Mayo Clinic, Rochester

🇺🇸

Rochester, Minnesota, United States

Creighton University

🇺🇸

Omaha, Nebraska, United States

Yale University School of Medicine

🇺🇸

New Haven, Connecticut, United States

University of Florida College of Medicine

🇺🇸

Jacksonville, Florida, United States

Pulmonary and Sleep of Tampa Bay

🇺🇸

Brandon, Florida, United States

Loyola University Medical Center

🇺🇸

Maywood, Illinois, United States

Pulmonary and Critical Care Associates of Baltimore

🇺🇸

Towson, Maryland, United States

The Lung Research Center, LLC

🇺🇸

Chesterfield, Missouri, United States

Dartmouth-Hitchcock Medical Center

🇺🇸

Lebanon, New Hampshire, United States

Columbia University Medical Center-New York Presbyterian Hospital

🇺🇸

New York, New York, United States

The Oregon Clinic

🇺🇸

Portland, Oregon, United States

NewYork-Presbyterian/Weill Cornell Medical Center

🇺🇸

New York, New York, United States

University of Pennsylvania

🇺🇸

Philadelphia, Pennsylvania, United States

University of Utah Health Sciences Center

🇺🇸

Salt Lake City, Utah, United States

Centro Dr. Lazaro Langer S.R.L

🇦🇷

Alberdi Sur, Argentina

Inova Fairfax Medical Campus

🇺🇸

Falls Church, Virginia, United States

CEMER-Centro Medico De Enfermedades Respiratorias

🇦🇷

Florida, Argentina

Centro de Investigaciones Metabólicas (CINME)

🇦🇷

C.a.b.a, Argentina

INSARES

🇦🇷

Mendoza, Argentina

Instituto Médico de la Fundación Estudios Clínicos

🇦🇷

Rosario, Argentina

UZ Leuven

🇧🇪

Leuven, Belgium

Centre Hospitalier Universitaire de Liège

🇧🇪

Liège, Belgium

Yvoir - UNIV UCL de Mont-Godinne

🇧🇪

Yvoir, Belgium

ULB Hopital Erasme

🇧🇪

Bruxelles, Belgium

Peking Union Medical College Hospital

🇨🇳

Beijing, China

CHUS Fleurimont

🇨🇦

Sherbrooke, Quebec, Canada

Hospital Clínico Reg. de Concepción "Dr. G. Grant Benavente"

🇨🇱

Concepción, Chile

Centro de Investigación del Maule

🇨🇱

Talca, Chile

Instituto Nacional del Tórax

🇨🇱

Providencia, Santiago De Chile, Chile

HOP Louis Pradel

🇫🇷

Bron, France

HOP Bretonneau

🇫🇷

Tours, France

The First Hospital of China Medical University

🇨🇳

Shenyang, China

HOP Côte de Nacre

🇫🇷

Caen, France

Nanjing Drum Tower Hospital

🇨🇳

Nanjing, China

HOP Avicenne

🇫🇷

Bobigny, France

CHRU Lille

🇫🇷

Lille, France

HOP Arnaud de Villeneuve

🇫🇷

Montpellier, France

HOP Bichat

🇫🇷

Paris, France

HOP Pontchaillou

🇫🇷

Rennes, France

HOP Maison Blanche

🇫🇷

Reims, France

Universitätsklinikum Bonn AöR

🇩🇪

Bonn, Germany

Fachkrankenhaus Coswig GmbH

🇩🇪

Coswig, Germany

Klinik Donaustauf

🇩🇪

Donaustauf, Germany

Medizinische Hochschule Hannover

🇩🇪

Hannover, Germany

Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH

🇩🇪

Essen, Germany

Petrus-Krankenhaus

🇩🇪

Wuppertal, Germany

Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg

🇩🇪

Heidelberg, Germany

A.O. San Gerardo di Monza

🇮🇹

Monza, Italy

Ospedale "G.B. Morgagni - L. Pierantoni" ausl forli

🇮🇹

Forli', Italy

Azienda Ospedaliera Policlinico di Modena

🇮🇹

Modena, Italy

Tosei General Hospital

🇯🇵

Aichi, Seto, Japan

Sapporo Medical University Hospital

🇯🇵

Hokkaido, Sapporo, Japan

Kurume University Hospital

🇯🇵

Fukuoka, Kurume, Japan

Kobe City Medical Center General Hospital

🇯🇵

Hyogo, Kobe, Japan

Ibarakihigashi National Hospial

🇯🇵

Ibaraki, Naka-gun, Japan

Kanagawa Cardiovascular and Respiratory Center

🇯🇵

Kanagawa, Yokohama, Japan

Saiseikai Kumamoto Hospital

🇯🇵

Kumamoto, Kumamoto, Japan

National Hospital Organization Kinki-Chuo Chest Medical Center

🇯🇵

Osaka, Sakai, Japan

Tohoku University Hospital

🇯🇵

Miyagi, Sendai, Japan

Osaka Medical College Hospital

🇯🇵

Osaka, Takatsuki, Japan

Hamamatsu University Hospital

🇯🇵

Shizuoka, Hamamatsu, Japan

Tokushima University Hospital

🇯🇵

Tokushima, Tokushima, Japan

Tokyo Medical and Dental University Hospital

🇯🇵

Tokyo, Bunkyo-ku, Japan

JR Tokyo General Hospital

🇯🇵

Tokyo, Shibuya-ku, Japan

University Clinical Center, Gdansk

🇵🇱

Gdansk, Poland

Center Hospital of the National Center for Global Health and Medicine

🇯🇵

Tokyo, Shinjuku-ku, Japan

Leszek Giec Upper-Silesian Med.Cent.Silesian Med.Univ.

🇵🇱

Katowice, Poland

Central Scientific Research Insitute of Tuberculosis

🇷🇺

Moscow, Russian Federation

Norbert Barlicki University Clinical Hospital No.1, Lodz

🇵🇱

Lodz, Poland

The Catholic University of Korea, Bucheon St.Mary's Hospital

🇰🇷

Bucheon, Korea, Republic of

Seoul National University Bundang Hospital

🇰🇷

Seongnam, Korea, Republic of

Asan Medical Center

🇰🇷

Seoul, Korea, Republic of

Nat.Instit.of Tuberculosis&LungDiseases,Outpat.Clin,warszawa

🇵🇱

Warszawa, Poland

Clinical Hospital No. 1, n.a. Prof. Szyszko from Silesian MA

🇵🇱

Zabrze, Poland

Res.Inst.-Compl.Iss.Cardi.Dis.

🇷🇺

Kemerovo, Russian Federation

Emergency Clinical Hospital n. a. N. V. Solovyev, Yaroslavl

🇷🇺

Yaroslavl, Russian Federation

Hospital de Bellvitge

🇪🇸

L'Hospitalet de Llobregat, Spain

Hospital de Canarias

🇪🇸

San Cristóbal de La Laguna, Spain

Hospital La Princesa

🇪🇸

Madrid, Spain

Hospital de Galdakao

🇪🇸

Galdakao, Spain

Hospital Central de Asturias

🇪🇸

Oviedo, Spain

Hospital Son Espases

🇪🇸

Palma de Mallorca, Spain

St James's University Hospital

🇬🇧

Leeds, United Kingdom

Royal Infirmary of Edinburgh

🇬🇧

Edinburgh, United Kingdom

Hospital Virgen del Rocío

🇪🇸

Sevilla, Spain

Wythenshawe Hospital

🇬🇧

Manchester, United Kingdom

University Hospital Llandough

🇬🇧

Penarth, United Kingdom

Penn State Milton S. Hershey Medical Center

🇺🇸

Hershey, Pennsylvania, United States

Baylor University Medical Center

🇺🇸

Dallas, Texas, United States

Toranomon Hospital

🇯🇵

Tokyo, Minato-ku, Japan

Moscow 1st State Med.Univ.n.a.I.M.Sechenov

🇷🇺

Moscow, Russian Federation

Royal Brompton Hospital

🇬🇧

London, United Kingdom

University of Kansas Medical Center

🇺🇸

Kansas City, Kansas, United States

St. Joseph's Healthcare Hamilton

🇨🇦

Hamilton, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath